Why You Should Account for Generics When Thinking About U.S. Prices, and How the IRA Will Raise Prices for Seniors
Shares:
Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv
Inflection Point The thorniest problem in biopharmaceuticals is the growing conflict between cost-effectiveness and budget impact. In other words, we increasingly have weapons against disease that are, objectively and
I often act all exasperated when data emerges that shows that the net prices of medicines are going down, feigning frustration at the fact that there has been limited recognition